Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients

Cancer Science

Volumn 104, Issue 4, 2013, Pages 437-444

  Herrera, Mercedes ^a   Herrera, Alberto ^a   Domínguez, Gemma ^a   Silva, Javier ^a   García, Vanesa ^a   García, José M ^a   Gómez, Irene ^a   Soldevilla, Beatriz ^a   Muñoz, Concepción ^b   Provencio, Mariano ^a   Campos Martin, Yolanda ^c   García de Herreros, Antonio ^d   Casal, Ignacio ^e   Bonilla, Félix ^a   Peña, Cristina ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b Departments of Gastroenterology   (Spain)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALVASCULIN; CD163 ANTIGEN; CELL PROTEIN; DCSIGN PROTEIN; FIBROBLAST ACTIVATION PROTEIN; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE FREE SURVIVAL; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FIBROBLASTS; HUMANS; MACROPHAGES; MALE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84875598884     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12096     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2006; 5: 106-30.
2. Libutti SK, Saltz LB, Tepper JE. Colon Cancer. In: Libutti SK, Saltz LB, Tepper JE, eds. Principles & Practice of Oncology, 8th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2008; 1232-85.
3. Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 2001; 11: 54-9.
4. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001; 1: 46-54.
5. Li H, Fan X, Houghton J. Tumor microenviroment: the role of the tumor stroma in cancer. J Cell Biochem 2007; 101: 805-15.
6. Xouri G, Christian S. Origin and function of tumor stroma fibroblasts. Semin Cell Dev Biol 2010; 21: 40-6.
7. Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res 2010; 316: 2713-22.
8. Beacham DA, Cukierman E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 2005; 15: 329-41.
9. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5: 1597-601.
10. Gout S, Huot J. Role of cancer microenvironment in metastasis: focus on colon cancer. Cancer Microenviron 2008; 1: 69-83.
11. Sugimoto H, Mundel TM, Kieran MW, Kalluri R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 2006; 5: 1640-6.
12. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
13. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008; 222: 155-61.
14. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44.
15. Ojalvo LS, King W, Cox D, Pollard JW. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol 2009; 174: 1048-64.
16. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-52.
17. Domínguez-Soto A, Sierra-Filardi E, Puig-Kröger A et al. Dendritic cell-specific ICAM-3-grabbing nonintegrin expression on M2-polarized and tumor-associated macrophages is macrophage-CSF dependent and enhanced by tumor-derived IL-6 and IL-10. J Immunol 2011; 186: 2192-200.
18. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-69.
19. Nakayama Y, Nagashima N, Minagawa N et al. Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. Anticancer Res 2002; 22: 4291-6.
20. Kwak JM, Lee HJ, Kim SH et al. Expression of protein S100A4 is a predictor of recurrence in colorectal cancer. World J Gastroenterol 2010; 16: 3897-904.
21. Tsujino T, Seshimo I, Yamamoto H et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res 2007; 13: 2082-90.
22. Henry LR, Lee HO, Lee JS et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007; 13: 1736-41.
23. Gomez I, Peña C, Herrera M et al. TWIST1 is expressed in colorectal carcinomas and predicts patient survival. PLoS ONE 2011; 6: e18023.
24. Peña C, García JM, Larriba MJ et al. SNAI1 expression in colon cancer related with CDH1 and VDR downregulation in normal adjacent tissue. Oncogene 2009; 28: 4375-85.
25. Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
26. Augsten M, Hägglöf C, Peña C, Östman A. A digest on the role of the tumor microenvironment in gastrointestinal cancers. Cancer Microenviron 2010; 3: 167-76.
27. Saadi A, Shannon NB, Lao-Sirieix P et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A 2010; 107: 2177-82.
28. Nakagawa H, Liyanarachchi S, Davuluri RV et al. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene 2004; 23: 7366-77.